Table 1.
Event rate at short term follow up, number needed to treat, and events avoided per 1000 patients treated in randomised clinical trials comparing primary angioplasty and fibrinolysis.
| 30-day events | PTCA (%, n) | Lysis (%, n) | p Value | OR (95%CI) | ARR% | NNT | NEA × 1000 |
| Mortality | |||||||
| Weaver10 | 4.4%, 57/1290 | 6.5%, 86/1316 | 0.02 | 0.66 (0.46 to 0.94) | 2.1 | 47 | 21/1000 |
| GUSTO II-B7 | 5.7%, 32/565 | 7.0%, 40/573 | 0.37 | 0.80 (0.49 to 1.30) | 1.3 | 77 | 13/1000 |
| SHOCK8* | 46.7%, 71/152 | 56%, 84/150 | 0.11 | 0.83 (0.67 to 1.04) | 9.3 | 11 | 91/1000 |
| C-PORTw46 | 5.3%, 12/225 | 6.2%, 14/226 | 0.7 | Not available | 0.9 | 111 | 9/1000 |
| DANAMI-2† | 6.6%, 52/790 | 7.6%, 59/782 | 0.35 | Not available | 1.0 | 100 | 10/1000 |
| Mortality or non-fatal reinfarction | |||||||
| Weaver | 7.2%, 94/1290 | 11.9%, 156/1316 | <0.001 | 0.58 (0.44 to 0.76) | 4.7 | 21 | 48/1000 |
| GUSTO-IIB | 9.6%, 54/565 | 12.2%, 70/573 | 0.08 | 0.72 (0.49 to 1.05) | 3.1 | 32 | 31/1000 |
| C-PORT‡ | 9.8%, 22/225 | 16.8%, 38/226 | 0.03 | 0.52 (0.30 to 0.89) | 7 | 14 | 71/1000 |
| DANAMI-2†‡ | 8.0%, 63/790 | 13.7%, 107/782 | 0.0003 | Not available | 5.7 | 18 | 55/1000 |
| Stroke | |||||||
| Weaver | 0.7%, 9/1290 | 2.0%, 26/1316 | 0.007 | 0.35 (0.14 to 0.77) | 1.3 | 77 | 13/1000 |
| PAMIw27 | 0 | 3.5%, 7/200 | 0.01 | Not available | 3.5 | 29 | 34/1000 |
| Zijlstra16 | 0.7%, 1/152 | 2.0%, 3/149 | 0.6 | 0.32 (0.01 to 4.08) | 1.3 | 77 | 13/1000 |
| GUSTO II-B | 1.1%, 6/565 | 1.9%, 11/573 | 0.34 | 0.54 (0.17 to 1.63) | 0.8 | 125 | 8/1000 |
| C-PORT | 1.3%, 3/225 | 3.5%, 8/226 | 0.13 | Not available | 2.2 | 45 | 22/1000 |
| DANAMI-2† | 1.1%, 8/790 | 2.0%, 15/782 | 0.15 | Not available | 0.9 | 111 | 9/1000 |
| Haemorrhagic stroke | |||||||
| Weaver | 0.1%, 1/1290 | 1.1%, 15/1316 | <0.001 | 0.07 (0.0 to 0.43) | 1 | 100 | 10/1000 |
| PAMI | 0 | 2.0%, 4/200 | 0.05 | Not available | 2 | 50 | 20/1000 |
| Zijlstra | 0.7%, 1/152 | 1.3%, 2/149 | 0.98 | 0.49 (0.01 to 9.47) | 0.6 | 166 | 6/1000 |
| GUSTO-IIB | 0 | 1.4%, 8/573 | 0.007 | Not available | 1.4 | 71 | 14/1000 |
*The SHOCK trial did not compare PTCA with lysis, but a strategy of emergency revascularisation versus initial medical stabilisation.
†Data not published. Presented at the scientific sessions of the American College of Cardiology, March 2002.
‡Includes disabling stroke.
ARR, absolute risk reduction; NEA × 1000, number of events avoided per 1000 patients treated; NNT, number needed to treat.